After adjustment for age; sex; BMI; emergency status; AKI stage; the presence of CKD, diabetes, hypertension, heart disease, or cancer; creatinine; ALB; cholesterol; triglyceride; Hb; eGFR; RRT requirement; and the use of ACEIs, ARBs, beta blockers, CCBs, furosemide and UA-lowering agents, a similar trend was observed in analysis of model 2. This evidence concerns the gene GSTM1 and diabetes mellitus.